Increased Serum WISP1 Levels are Associated with Lower Extremity Atherosclerotic Disease in Patients with Type 2 Diabetes Mellitus

Abstract

Background Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are increased with obesity, which is a common complication associated with lower extremity atherosclerotic disease (LEAD). However, to date, the relationship between elevated WISP1 levels and the incidence of lower extremity atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains unclear.

Methods 174 newly diagnosed type 2 diabetic patients were enrolled in our study. Patients were divided into two groups, LEAD group (n=100) and control group (n=74). Anthropometric parameters, blood pressure and some biochemical parameters were obtained. Body composition was detected by bioelectrical impedance analysis (BIA). Levels of serum insulin were determined by radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined using an enzyme-linked immunosorbent assay.

Results It was shown that serum WISP1 levels in diabetic patients with LEAD were higher than those without LEAD (P<0.001). Serum WISP1 levels were positively related with waist circumference (r=0.237, P=0.003), waist-hip ratio (r=0.22, P=0.006), visceral fat area (r=0.354, P<0.001), serum creatinine (r=0.192, P=0.012), interleukin 6 (r=0.182, P=0.032), c-reactive protein (r=0.681, P<0.001), triglycerides (r=0.119, P<0.001), fasting glucose (r=0.196, P=0.011), glycated hemoglobin (r=0.284, P<0.001), and HOMA-IR (r=0.285, P<0.026). Compared with the lowest tertile, the odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24–8.64) and 4.46 (95% CI, 1.62–12.29) for the highest tertile after adjusting confounding factors.

Conclusion The results suggest that increased serum WISP1 levels independently contribute to the incidence of LEAD in patients with newly diagnosed T2DM.

Key words

Wnt1-induced signaling pathway protein 1 - lower extremity atherosclerotic disease - type 2 diabetes mellitus - obesity - inflammation - insulin resistance

Publication History

Received: 10 January 2021
Received: 17 March 2021

Accepted: 26 March 2021

Article published online:
30 April 2021

• References

• 1 Kamil S, Sehested TSG, Carlson N. et al. Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study. Bmc Cardiovasc Disor 2019; 19: 234 DOI: 10.1186/s12872-019-1213-1.
• 2 Mukherjee D. Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus. Best Pract Res Cl En 2009; 23: 335-345 DOI: 10.1016/j.beem.2008.10.015.
• 3 Beckman JA, Creager MA. Libby P. Diabetes and Atherosclerosis. Jama 2002; 287: 2570 DOI: 10.1001/jama.287.19.2570.
• 4 Laclaustra M, Casasnovas JA, Fernández-Ortiz A. et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium. J Am Coll Cardiol 2016; 67: 1263-1274 DOI: 10.1016/j.jacc.2015.12.056.
• 5 Yamada K, Yasunaga H, Kadono Y. et al. Postoperative outcomes of major lower extremity amputations in patients with diabetes and peripheral artery disease: Analysis using the Diagnosis Procedure Combination database in Japan. Am J Surg 2016; 212: 446-450 DOI: 10.1016/j.amjsurg.2015.08.039.
• 6 Collaboration ABI, Fowkes FGR, Murray GD. et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. Jama 2008; 300: 197-208 DOI: 10.1001/jama.300.2.197.
• 7 Vrsalovic M, Vucur K, Presecki AV. et al. Impact of diabetes on mortality in peripheral artery disease: A meta-analysis: Diabetes and mortality in peripheral artery disease: A meta-analysis. Clin Cardiol 2016; 40: 287-291 DOI: 10.1002/clc.22657.
• 8 Berschneider B, Königshoff M. WNT1 inducible signaling pathway protein 1 (WISP1): A novel mediator linking development and disease. Int J Biochem Cell Biol 2011; 43: 306-309 DOI: 10.1016/j.biocel.2010.11.013.
• 9 Deng W, Fernandez A, McLaughlin SL. et al. WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial–mesenchymal transition. J Biol Chem 2019; 294: 5261-5280 DOI: 10.1074/jbc.ra118.006122.
• 10 Venkatachalam K, Venkatesan B, Valente AJ. et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 2009; 284: 14414-14427 DOI: 10.1074/jbc.m809757200.
• 11 Murahovschi V, Pivovarova O, Ilkavets I. et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 2015; 64: 856-866 DOI: 10.2337/db14-0444.
• 12 Hörbelt T, Tacke C, Markova M. et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia 2018; 61: 2054-2065 DOI: 10.1007/s00125-018-4636-9.
• 13 Klimontov VV, Bulumbaeva DM, Fazullina ON. et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal 2019; 1-9 DOI: 10.1007/s12079-019-00536-4.
• 14 Bedel A, Nègre-Salvayre A, Heeneman S. et al. E-cadherin/beta-catenin/T-cell factor pathway is involved in smooth muscle cell proliferation elicited by oxidized low-density lipoprotein. Circ Res 2008; 103: 694-701 DOI: 10.1161/circresaha.107.166405.
• 15 Gu L, Chen N, Li Z. et al. Relationship of serum Wnt1-inducible signaling pathway protein 1 levels with coronary artery disease and its severity. Coronary Artery Disease 2019; 1 DOI: 10.1097/mca.0000000000000745.
• 16 Aboyans V, Ricco J-B, Bartelink M-LEL. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2017; 39: 763-816 DOI: 10.1093/eurheartj/ehx095.
• 17 Tacke C, Aleksandrova K, Rehfeldt M. et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal 2018; 12: 539-548 DOI: 10.1007/s12079-017-0427-1.
• 18 Roever LS, Resende ES, Diniz ALD. et al. Abdominal obesity and association with atherosclerosis risk factors: The Uberlândia Heart Study. Medicine 2016; 95: e1357 DOI: 10.1097/md.0000000000001357.
• 19 Barchetta I, Cimini FA, Capoccia D. et al. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc 2017; 1: 660-670 DOI: 10.1210/js.2017-00108.
• 20 Geovanini GR, Libby P. Atherosclerosis and inflammation: Overview and updates. Clin Sci 2018; 132: 1243-1252 DOI: 10.1042/cs20180306.
• 21 Pino AD, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019; 40: 1447-1467 DOI: 10.1210/er.2018-00141.
• 22 Ersoy G, Ensari T, Subas S. et al. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Fetal Neonatal Med 2016; 30: 1-5 DOI: 10.1080/14767058.2016.1192118.
• 23 Ersoy GS, Ensari TA, Vatansever D. et al. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol Endocrinol 2016; 33: 1-5 DOI: 10.1080/09513590.2016.1223286.
• 24 Borrell-Pagès M, Romero JC, Badimon L. LRP5 deficiency down-regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice. J Cell Mol Med 2015; 19: 770-777 DOI: 10.1111/jcmm.12396.
• 25 Jung TW, Kang C, Goh J. et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 2018; 233: 6077-6087 DOI: 10.1002/jcp.26449.
• 26 Colston JT, Rosa de la SD, Koehler M. et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol-heart C 2007; 293: H1839-H1846 DOI: 10.1152/ajpheart.00428.2007.
• 27 Chistiakov DA, Sobenin IA, Orekhov AN. Vascular extracellular matrix in atherosclerosis. Cardiol Rev 2013; 21: 270-288 DOI: 10.1097/crd.0b013e31828c5ced.
• 28 Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712-723 DOI: 10.1038/nri2852.
• 29 Ahmad K, Lee EJ, Moon JS. et al. Multifaceted interweaving between extracellular matrix, insulin resistance, and skeletal muscle. Cells 2018; 7: 148 DOI: 10.3390/cells7100148.
• 30 Sala LL, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol 2019; 26: 15-24 DOI: 10.1177/2047487319878373.
• 31 PLSM Gordts, Esko JD. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biol 2018; 71–72: 262-282 DOI: 10.1016/j.matbio.2018.05.010.
• 32 Wang A, Yan X, Zhang C. et al. Characterization of Wnt1-inducible signaling pathway protein-1 in obese children and adolescents. Curr Medical Sci 2018; 38: 868-874 DOI: 10.1007/s11596-018-1955-5.
• 33 Habib NS, EL-Hefnawy MH, El-Mesallamy HO. Assessment of circulating Wnt1-inducible signaling pathway protein 1 (WISP1) in obesity and type 2 diabetes mellitus patients. Archives of Pharmaceutical Sciences Ain Shams University 2018; 2: 47-53 DOI: 10.21608/aps.2018.18734.